• Profile
Close

Antipsychotic use and risk of breast cancer in women with schizophrenia: A nationwide nested case-control study in Finland

The Lancet Psychiatry Sep 23, 2021

Taipale H, Solmi M, Lähteenvuo M, et al. - Researchers herein reported correlation between receiving treatment with prolactin-increasing antipsychotics and increased odds of breast cancer.

  • A nested case-control study was performed using data from Finnish nationwide registers of hospital treatment, prescription drug purchases, and cancer diagnoses.

  • From 1972 and 2014, 30,785 women were identified who were diagnosed with schizophrenia; breast cancer was diagnosed in 1,069 of these women between January 1, 2000, and December 31, 2017.

  • The cases were matched by age and duration of illness to a total of 5,339 women without cancer (controls).

  • Increased odds of breast cancer are recorded in significant correlation with long-term exposure to prolactin-increasing, but not to prolactin-sparing, antipsychotics.

  • Long-term use of prolactin-increasing antipsychotics is linked with greater risk of developing lobular adenocarcinoma than that of developing ductal adenocarcinoma.

  • In women with schizophrenia receiving treatment with prolactin-increasing antipsychotics, it is paramount to monitor prolactinemia and address hyperprolactinemia.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay